PHESGO™ PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

What it Treats PHESGO ™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PHESGO should be used as part…

Read More

Thousands of patients set to benefit from five-minute breast cancer treatment

By Yusef AlamReporter Share   Thousands of patients set to benefit from five-minute breast cancer treatment AN INJECTION which cuts the amount of time breast cancer patients spend in hospital from two-and-a-half-hours to as little as five minutes is being rolled out across the country by NHS England. Breast cancer patients undergoing chemotherapy will be…

Read More

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Meagan P. O’Brien, M.D., Eduardo Forleo-Neto, M.D., Bret J. Musser, Ph.D., Flonza Isa, M.D., Kuo-Chen Chan, Ph.D., Neena Sarkar, Ph.D., Katharine J. Bar, M.D., Ruanne V. Barnabas, M.D., Dan H. Barouch, M.D., Ph.D., Myron S. Cohen, M.D., Christopher B. Hurt, M.D., Dale R. Burwen, M.D., M.P.H.,  for the Covid-19 Phase 3 Prevention Trial Team* BACKGROUND…

Read More

Emerging Biomarkers and Targeting Therapies in Feline Mannary Carcinoma

Andreia Gameiro 1, Ana Catarina Urbano 1, Fernando Ferreira 1 Affiliations expand PMID: 34437486 PMCID: PMC8402877 DOI: 10.3390/vetsci8080164 Free PMC article Abstract Feline mammary carcinoma (FMC) is a common aggressive malignancy with a low survival rate that lacks viable therapeutic options beyond mastectomy. Recently, increasing efforts have been made to understand the molecular mechanisms underlying FMC development, using the knowledge gained from studies on…

Read More

Pertuzumab and trastuzumab: the rationale way to synergy

Sandrine Richard 1, Frédéric Selle 1, Jean-Pierre Lotz 1 2, Ahmed Khalil 1, Joseph Gligorov 1 2, Daniele G Soares 1 Affiliations expand PMID: 27275646 DOI: 10.1590/0001-3765201620150178 Free article Abstract It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease,…

Read More

The top 10 antibody-drug conjugate contenders in 2021

By Arlene WeintraubSep 13, 2021 12:00am Fierce Pharma’s list of top antibody-drug conjugate contenders includes a mix of Big Pharma players and startups that are expecting major milestones in the coming months. (PDPics/Pixabay) After Pfizer launched Mylotarg, the first antibody-drug conjugate (ADC) in 2000, it seemed to be the long-awaited “magic bullet” in cancer; it was a drug…

Read More

Pertuzumab plus trastuzumab in metastatic breast cancer

Mehmet A N Şendur, Sercan Aksoy, Nurullah Zengin PMID: 22475602 DOI: 10.1056/NEJMc1201462 Comment on Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.N Engl J Med. 2012 Jan…

Read More

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight on messenger RNA (mRNA)—the molecule that carries a cell’s instructions for making proteins. Hundreds of millions of people worldwideExit Disclaimer have received mRNA vaccines that provide powerful protection against severe COVID-19 caused by infection with SARS-CoV-2.…

Read More